Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/​Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody

2024-515650-24-00 Protocol CARTBCMA-HCB-01 Therapeutic exploratory (Phase II) Ended

Start 26 Jul 2024 · End 7 Nov 2025 · Status Ended · 1 EU/EEA countries · 7 sites · Protocol CARTBCMA-HCB-01

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ended
Participants planned 30
Countries 1
Sites 7

Multiple Myeloma

Key facts

Sponsor
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
26 Jul 2024 → 7 Nov 2025
Decision date (initial)
2024-07-26
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-515650-24-00
EudraCT number
2019-001472-11
ClinicalTrials.gov
NCT04309981

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple Myeloma

VersionLevelCodeTermSystem organ class
21.0 LLT 10028228 Multiple myeloma 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Sponsor organisation
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Address
Calle Rosellon 149-153
City
Barcelona
Postcode
08036
Country
Spain

Scientific contact point

Organisation
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Contact name
Carlos Fernandez de Larrea

Public contact point

Organisation
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Contact name
Carlos Fernandez de Larrea

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 30 7
Rest of world 0

Investigational sites

Spain

7 sites · Ended
Hospital Clinic De Barcelona
Haematology, Calle Villarroel 170, 08036, Barcelona
Clinica Universidad De Navarra
Haematology, Pio XII Etorbidea 36, 31008, Pamplona
University Hospital Virgen Del Rocio S.L.
Haematology, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Universitario De Salamanca
Haematology, Paseo De San Vicente 58-182, 37007, Salamanca
University Clinical Hospital Virgen De La Arrixaca
Haematology, Carretera Madrid-Cartagena S/N, El Palmar, Murcia
Complexo Hospitalario Universitario De Santiago
Haematology, Calle Choupana Da S/n, 15706, Santiago De Compostela
Hospital Universitario 12 De Octubre
Haematology, Bloque D, Avenida De Cordoba Sn, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2024-07-26 2025-11-07 2024-07-26 2024-07-26

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-15 Spain Acceptable
2024-07-26
2024-07-26